User login
Key clinical point: Long-term treatment with lasmiditan is associated with progressive and clinically meaningful reductions in migraine-related disability, including fewer missed days of work and school.
Major finding: Total scores of Migraine Disability Assessment (MIDAS) scale significantly reduced from baseline to months 3, 6, 9, and 12 for both 100 and 200 mg doses of lasmiditan, with no significant differences between the dose groups. Work and/or school absenteeism and presenteeism, monthly headache days, and mean headache pain intensity improved significantly with lasmiditan for up to 1 year.
Study details: Patients in GLADIATOR trial were randomly assigned to lasmiditan 100 mg (n=974) or 200 mg (n=1063).
Disclosures: The GLADIATOR study was funded by Eli Lilly and Company. The presenting author had received consultant fees, honoraria, and/or research grants from various pharmaceutical companies, including Eli Lilly and Company. Five of the authors were employees and minor stockholders of Eli Lilly and Company and one was an employee of Syneos Health, Inc., under contract to Eli Lilly and Company.
Citation: Lipton RB et al. J Headache Pain. 2020 Feb 24. doi: 10.1186/s10194-020-01088-4.
Key clinical point: Long-term treatment with lasmiditan is associated with progressive and clinically meaningful reductions in migraine-related disability, including fewer missed days of work and school.
Major finding: Total scores of Migraine Disability Assessment (MIDAS) scale significantly reduced from baseline to months 3, 6, 9, and 12 for both 100 and 200 mg doses of lasmiditan, with no significant differences between the dose groups. Work and/or school absenteeism and presenteeism, monthly headache days, and mean headache pain intensity improved significantly with lasmiditan for up to 1 year.
Study details: Patients in GLADIATOR trial were randomly assigned to lasmiditan 100 mg (n=974) or 200 mg (n=1063).
Disclosures: The GLADIATOR study was funded by Eli Lilly and Company. The presenting author had received consultant fees, honoraria, and/or research grants from various pharmaceutical companies, including Eli Lilly and Company. Five of the authors were employees and minor stockholders of Eli Lilly and Company and one was an employee of Syneos Health, Inc., under contract to Eli Lilly and Company.
Citation: Lipton RB et al. J Headache Pain. 2020 Feb 24. doi: 10.1186/s10194-020-01088-4.
Key clinical point: Long-term treatment with lasmiditan is associated with progressive and clinically meaningful reductions in migraine-related disability, including fewer missed days of work and school.
Major finding: Total scores of Migraine Disability Assessment (MIDAS) scale significantly reduced from baseline to months 3, 6, 9, and 12 for both 100 and 200 mg doses of lasmiditan, with no significant differences between the dose groups. Work and/or school absenteeism and presenteeism, monthly headache days, and mean headache pain intensity improved significantly with lasmiditan for up to 1 year.
Study details: Patients in GLADIATOR trial were randomly assigned to lasmiditan 100 mg (n=974) or 200 mg (n=1063).
Disclosures: The GLADIATOR study was funded by Eli Lilly and Company. The presenting author had received consultant fees, honoraria, and/or research grants from various pharmaceutical companies, including Eli Lilly and Company. Five of the authors were employees and minor stockholders of Eli Lilly and Company and one was an employee of Syneos Health, Inc., under contract to Eli Lilly and Company.
Citation: Lipton RB et al. J Headache Pain. 2020 Feb 24. doi: 10.1186/s10194-020-01088-4.